BRNS
6:57 PM
Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics
Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open Topco common stock expected to commence trading on Nasdaq
barinthusbio.com